Literature DB >> 6355318

Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. III. Interruption of mother-to-infant transmission.

K M Boyer, C A Gadzala, P D Kelly, S P Gotoff.   

Abstract

The effect of intrapartum ampicillin treatment on vertical transmission of group B streptococci (GBS) was examined in 575 prenatally colonized parturient women and their 580 newborn infants. Eighty women (43 receiving ampicillin) with premature labor and/or prolonged rupture of amniotic membranes were randomized. The other 495 were stratified into groups of 358 (31 receiving ampicillin) with no perinatal risk factors; 119 (28 receiving ampicillin) with premature labor and/or prolonged membrane rupture; and 23 (18 receiving ampicillin) with intrapartum fever. Ampicillin virtually eliminated vertical transmission in the treatment group with no risk factors and in both treatment groups with premature labor and/or prolonged membrane rupture. GBS colonization of neonates was detected only in women with intrapartum fever or brief (less than 1 hr) duration of treatment prior to delivery. Ampicillin treatment was associated with a highly significant reduction in maternal postpartum vaginal colonization by GBS. There were six group B streptococcal early-onset infections in infants of untreated subjects and no cases in treated subjects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355318     DOI: 10.1093/infdis/148.5.810

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Interpretation of 2002 Centers for Disease Control guidelines for group B streptococcus and evolving provider practice patterns.

Authors:  Emma L Barber; Edmund F Funai; Michael B Bracken; Jessica L Illuzzi
Journal:  Am J Perinatol       Date:  2010-07-16       Impact factor: 1.862

2.  Adherence of Streptococcus agalactiae to synchronously growing human cell monolayers without lipoteichoic acid involvement.

Authors:  S Miyazaki; O Leon; C Panos
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

Review 3.  The preterm parturition syndrome.

Authors:  R Romero; J Espinoza; J P Kusanovic; F Gotsch; S Hassan; O Erez; T Chaiworapongsa; M Mazor
Journal:  BJOG       Date:  2006-12       Impact factor: 6.531

4.  Septic arthritis of the hip complicating pregnancy.

Authors:  J D Howell; R J Sheddon
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

5.  Rapid detection of group B streptococcal colonization of the genital tract by a commercial optical immunoassay.

Authors:  K C Carroll; D Ballou; M Varner; H Chun; R Traver; J Salyer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

6.  Evaluation of a rapid latex agglutination test for detection of group B streptococci in vaginal specimens.

Authors:  L Lotz-Nolan; T Amato; J Iltis; W Wallen; B Packer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

7.  Lim group B Strep Broth and coagglutination for rapid identification of group B streptococci in preterm pregnant women.

Authors:  D V Lim; W J Morales; A F Walsh
Journal:  J Clin Microbiol       Date:  1987-02       Impact factor: 5.948

8.  Assessment of two methods for rapid intrapartum detection of vaginal group B streptococcal colonisation.

Authors:  A J Simpson; J A Mawn; S R Heard
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

9.  Comparison of different sampling techniques and of different culture methods for detection of group B streptococcus carriage in pregnant women.

Authors:  Nabil A El Aila; Inge Tency; Geert Claeys; Bart Saerens; Piet Cools; Hans Verstraelen; Marleen Temmerman; Rita Verhelst; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2010-09-29       Impact factor: 3.090

10.  Rapid detection of group B streptococci directly from vaginal swabs.

Authors:  E R Wald; B Dashefsky; M Green; J Harger; M Parise; C Korey; C Byers
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.